NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells

Table 2 Univariate analyses of factors associated with survival and recurrence

Clinical and pathologic indexes		OS		RFS
Clinical and pathologic indexes		HR (95%CI)	P	HR (95%CI)	P
Age, years	(≤ 50 vs. > 50)	0.98 (0.78,1.23)	0.873	0.82 (0.66,1.00)	0.055
Gender	(Male vs. female)	1.21 (0.87,1.69)	0.235	1.14 (0.85,1.53)	0.389
HBsAg	(Positive vs. negative)	2.95 (2.35,3.71)	0.000	2.83 (2.27,3.53)	0.000
Liver cirrhosis	(No vs. yes)	0.52 (0.17,1.63)	0.210	0.37 (0.119,1.154)	0.087
GGT (U/L)	(≤ 54 vs. > 54)	0.95 (0.76,1.20)	0.666	0.94 (0.76,1.16)	0.540
AFP (ng/mL)	(> 400 vs. ≤400)	1.23 (0.99,1.53)	0.064	1.33 (1.09,1.63)	0.005
Tumor number	(Multiple vs. single)	1.33 (1.05,1.69)	0.017	1.64 (1.32,2.04)	0.000
Tumor size, cm	(> 5 vs. ≤ 5)	1.09 (0.88,1.35)	0.436	1.11 (0.90,1.35)	0.328
Tumor encapsulation	(Complete vs. none)	0.58 (0.46,0.72)	0.000	0.67 (0.55,0.82)	0.000
Edmondson stage	(I-II vs. II-IV)	0.73 (0.58,0.92)	0.008	0.67 (0.54,0.82)	0.000
BCLC stage	(0-A vs. B-C)	0.57 (0.43,0.76)	0.000	0.49 (0.38,0.64)	0.000
PVTT	(None vs. yes)	0.47 (0.34,0.58)	0.000	0.56 (0.46,0.68)	0.000
NLRX1	(Positive vs. negative)	0.55 (0.44,0.67)	0.000	0.47 (0.38,0.59)	0.000

Abbreviations: AFP α-fetoprotein, BCLC Barcelona Clinic Liver Cancer, CI confidence interval, HR hazard ratio, GGT gamma-glutamyl transpeptidase, HBsAg hepatitis B virus surface antigen, NLRX1 nucleotide-binding oligomerization domain-like receptor X1, OS overall survival, PVTT portal vein tumor thrombus, RFS recurrence-free survival

ISSN: 1756-8722